Action Bergenbio Asa - 0RU5

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

4 600,00

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

4 600,00 Plage de 52 semaines 4 600,00

Cap du marché

12,368T

Clôture Veille

4 600,00

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

3 080

Actions en circulation

2 688 689 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,28

Bénéfice par action (BPA)

-0,07

Chiffre d'affairess

354k

Bénéfice net

-190,4M

Secteur

Meas & Controlling Dev, Nec

Industrie

Meas & Controlling Dev, Nec

Site Web

www.bergenbio.com

Siège social

Bergen, Nor

Fondé

Bergenbio Asa est coté dans le secteur Meas & Controlling Dev de la London Stock Exchange avec le ticker 0RU5. Le dernier cours de clôture d'Bergenbio Asa était de kr4 600,00. Au cours de la dernière année, les actions de Bergenbio Asa ont été négociées dans une fourchette de prix de kr 4 600,00 à kr 4 600,00.

Bergenbio Asa compte actuellement 2 688 689 000 actions en circulation. La capitalisation boursière d'Bergenbio Asa est de kr12,37 billion. Bergenbio Asa a un ratio cours/bénéfice (ratio PE) de -0.28.

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA...

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung...

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE...

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	4600	4600	4600	0	0	DE
4	4600	4600	4600	7951	4600	DE
12	4600	4600	4600	3080	4600	DE
26	4600	4600	4600	1963	4600	DE
52	4600	4600	4600	7851	4600	DE
156	4600	4600	4600	76046	4600	DE
260	4600	4600	4600	47727	4600	DE

0RU5 - Frequently Asked Questions (FAQ)

What is the current Bergenbio Asa share price?

The current share price of Bergenbio Asa is kr 4 600,00

How many Bergenbio Asa shares are in issue?

Bergenbio Asa has 2 688 689 000 shares in issue

What is the market cap of Bergenbio Asa?

The market capitalisation of Bergenbio Asa is NOK 12,37T

What is the 1 year trading range for Bergenbio Asa share price?

Bergenbio Asa has traded in the range of kr 4 600,00 to kr 4 600,00 during the past year

What is the PE ratio of Bergenbio Asa?

The price to earnings ratio of Bergenbio Asa is -0,28

What is the cash to sales ratio of Bergenbio Asa?

The cash to sales ratio of Bergenbio Asa is 200

What is the reporting currency for Bergenbio Asa?

Bergenbio Asa reports financial results in NOK

What is the latest annual turnover for Bergenbio Asa?

The latest annual turnover of Bergenbio Asa is NOK 354k

What is the latest annual profit for Bergenbio Asa?

The latest annual profit of Bergenbio Asa is NOK -190,4M

What is the registered address of Bergenbio Asa?

The registered address for Bergenbio Asa is M��LLENDALSBAKKEN 9, BERGEN, 5009

What is the Bergenbio Asa website address?

The website address for Bergenbio Asa is www.bergenbio.com

Which industry sector does Bergenbio Asa operate in?

Bergenbio Asa operates in the MEAS & CONTROLLING DEV, NEC sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
IMMImmupharma Plc	4,00p (19,23%)	6,65M
STBSecure Trust Bank Plc	485,00p (15,48%)	80,01k
LMSLms Capital Plc	21,00p (14,13%)	262,08k
OBDOxford Biodynamics Plc	0,525p (10,53%)	10,01M
DFSDfs Furniture Plc	145,00p (10,52%)	486,34k
HRNHornby Plc	13,00p (-31,58%)	280,83k
BSFABsf Enterprise Plc	1,625p (-27,78%)	1,82M
SYMESupply@me Capital Plc	0,003p (-20,00%)	1,7M
CCRC&c Group Plc	120,40p (-18,54%)	1,18M
TRNTrainline Plc	272,00p (-13,32%)	980,48k
UKOGUk Oil & Gas Plc	0,01025p (7,89%)	243,79M
CPAICapai Plc	0,0835p (0,00%)	178,43M
ALBAAlba Mineral Resources	0,0105p (-4,55%)	37,51M
PREMPremier African Minerals Limited	0,01025p (-3,30%)	26,47M
EMEEmpyrean Energy Plc	0,1125p (-8,16%)	25,35M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bergenbio Asa (0RU5)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Bergenbio Asa

0RU5 Dernières nouvelles

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO

0RU5 - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bergenbio Asa (0RU5) Cours

Bergenbio Asa (0RU5)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Bergenbio Asa

0RU5 Dernières nouvelles

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO

0RU5 - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités